|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 3/06/24 Hepion Pharmaceuticals, Inc. 8-K:5 3/05/24 10:196K M2 Compliance LLC/FA |
Document/Exhibit Description Pages Size 1: 8-K Current Report HTML 34K 5: R1 Cover HTML 49K 7: XML IDEA XML File -- Filing Summary XML 11K 10: XML XBRL Instance -- form8-k_htm XML 16K 6: EXCEL IDEA Workbook of Financial Report Info XLSX 8K 3: EX-101.LAB XBRL Labels -- hepa-20240305_lab XML 96K 4: EX-101.PRE XBRL Presentations -- hepa-20240305_pre XML 64K 2: EX-101.SCH XBRL Schema -- hepa-20240305 XSD 12K 8: JSON XBRL Instance as JSON Data -- MetaLinks 25± 34K 9: ZIP XBRL Zipped Folder -- 0001493152-24-009028-xbrl Zip 14K
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): i March 5, 2024
i Hepion Pharmaceuticals, Inc.
(Exact name of registrant as specified in its charter)
| i Delaware | i 001-36856 | i 46-2783806 | ||
| (State or other jurisdiction | (Commission | (IRS Employer | ||
| of incorporation or organization) | File Number) | Identification No.) |
i 399 Thornall Street, i First Floor
(Address of principal executive offices)
Registrant’s telephone number, including area code: i (732) i 902-4000
(Former name or former address, if changed since last report)
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class: | Trading Symbol(s) | Name of each exchange on which registered: | ||
| i Common Stock | i HEPA | i Nasdaq Capital Market |
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company i ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. i ☒
Item 5.02 Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers.
On March 5, 2024, the Board of Directors of Hepion Pharmaceuticals, Inc. (the “Company”) appointed Michael Purcell as a director of the Company. In addition, Mr. Purcell was appointed as Chair of the Audit Committee and a member of the Compensation Committee and Corporate Governance/Nominations Committee.
| -2- |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Dated: March 6, 2024
| HEPION PHARMACEUTICALS, INC. | ||
| By: | /s/ John Cavan | |
| John Cavan | ||
| Interim Chief Executive Officer and Chief Financial Officer | ||
| -3- |
| This ‘8-K’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| Filed on: | 3/6/24 | None on these Dates | ||
| For Period end: | 3/5/24 | |||
| List all Filings | ||||